NCT01750086COMPLETEDanonymous

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Sponsor

Source record

Massachusetts General Hospital

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Indication / condition

AI-normalized

Postmenopausal Osteoporosis

Intervention

Source record

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Source & freshness

Source record

NCT ID

NCT01750086

Original source

ClinicalTrials.gov

Source last updated

Mar 27, 2017

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01750086

Title

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Sponsor

Massachusetts General Hospital

Status

COMPLETED

Phase

PHASE4

Condition raw

Postmenopausal Osteoporosis

Condition normalized

Postmenopausal Osteoporosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Target normalized

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Interventions

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Public preview

Source record

The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01750086

Status

COMPLETED

Phase

PHASE4

Sponsor

Massachusetts General Hospital

Executive brief

Investment-Ready Snapshot

The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 27, 2017

Internal syncMay 23, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01750086

Indication

Postmenopausal Osteoporosis

Modality

small molecule

Target

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Intervention

Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.